In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice

Japanese Journal of Cancer Research

Volumn 92, Issue 5, 2001, Pages 529-536

  Kosugi, Hiroshi ^a   Ito, Masafumi ^a   Yamamoto, Yukiya ^a   Towatari, Masayuki ^a   Ito, Mamoru ^b   Ueda, Ryuzo ^c   Saito, Hidehiko ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Differentiation; FK228; Histone deacetylase inhibitor

Indexed keywords

DEPSIPEPTIDE; FR 901228; HISTONE; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DRUG POTENTIATION; DRUG SENSITIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; SCID MOUSE; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CELL DIFFERENTIATION; DEPSIPEPTIDES; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; KINETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PEPTIDES, CYCLIC; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0034982359     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01126.x     Document Type: Article

References (42)

1. Acute promyelocytic leukemia
2. Acute promyelocytic leukemia: From genetics to treatment
3. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
4. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
5. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
6. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
7. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
8. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation
9. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway
10. Histone deacetylase: A regulator of transcription
11. The language of covalent histone modifications
12. Role of CBP/P300 in nuclear receptor signalling
13. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
14. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
15. Acute promyelocytic leukemia: Relieving repression induces remission
16. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
17. Role of the histone deacetylase complex in acute promyelocytic leukaemia
18. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
19. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy
20. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid
21. Effects of trichostatins on differentiation of murine erythroleukemia cells
22. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A
23. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway
24. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
25. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
26. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
27. Phase I trial and pharmacokinetic (PK) analysis of depsipeptide in patients with advanced cancer
28. A phase I study of FR901228 (Depsipeptide), a histone deacetylase inhibitor
29. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: Differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia
30. Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS
31. Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases
32. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
33. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
34. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase
35. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
36. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
37. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
38. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
39. Three proteins define a class of human histone deacetylases related to yeast Hda1p
40. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
41. Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice
42. Acute leukemia with promyelocytic features in PML/RARα transgenic mice